Drug Profile
Research programme: anticancer therapeutics - Merck KGaA
Alternative Names: Immuno-oncology antibody therapeutics - Merck KGaALatest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Merck KGaA
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 28 Jun 2021 No recent reports of development identified for research development in Cancer in Germany (Parenteral)
- 30 May 2017 Merck KGaA in-licenses SUREtechnology Platform™ and SURE CHO-M (suspension-adapted CHO-K1) cell line from Selexis